logo

- HanAll enters into the 60 billion KRW market with peptic ulcer drug \'Wibis Tab\'

- Wibis demondstrated sucessful bioequivalance to \'albis\', a triple combination drug to treat peptic ulcer originally developed by Daewoong Pharmaceutical   

- Signs consignment contract with Green Cross, Yuhan, and Whanin Pharm

​

HanAll Biopharma(CO-CEO Seong-uk Kim and Seung-kook Park) has announced the launch of their new peptic ulcer drug, \'Wibis\', on December 1st.

\'Wibis\', developed and launched by HanAll Biopharma, is a generic version of Albis, a renowned peptic ulcer drug manufactured by Daewoong Pharmaceutical. Albis achieved sales of 60 billion KRW in the peptic ulcer drug market last year. While several pharmaceutical companies attempted to develop generic versions of albis, the complex composition of the tablet posed challenges. Only Pharvis Korea and HanAll Biopharma successfully demonstrated bioequivalence.

To maximize the sales potential of Wibis Tab, HanAll Biopharma has entered into consignment contracts with Green Cross, Yuhan, and Whanin Pharmaceutical for product supply, with these companies approved for consignment production. In addition to Hanall\'s direct sales strategy, major pharmaceutical corporations are now distributing this product, ensuring a stable sales network.

An official from HanAll Biopharma explained, "To meet the demand for Wibis Tab and the composite drug \'HL040\' for hypertension and hyperlipidemia, pending approval from the Ministry of Food and Drug Safety after completing phase 3 clinical trials, we invested approximately 4 billion KRW last year to establish an exclusive plant for annual production of 600 million tablets and develop long-term strategies. Considering the significant market presence of Wibis Tab, which generates around 60 billion KRW in sales each year, we anticipate approximately 20 billion KRW in sales during the third year of sales, encompassing both direct and consignment sales."​